Healthcare Services for International Patients

Fortis Hospital, Bannerghatta Road successfully conducted 1080 robotic surgeries in 2023, setting new benchmarks in precision and excellence. With a multidisciplinary approach, the facility’s Centre of Excellence in Robotic Surgery caters to a diverse range of specialties, including Orthopaedics, Urology, Oncology, Gynaecology, Cardiac Surgery, and Gastroenterology. This comprehensive scope ensures that patients receive personalized care tailored to their specific medical needs. From knee replacements to kidney transplants to cancer and cardiac surgeries, the hospital is dedicated to achieving exceptional results. Leveraging state-of-the-art technologies like the Mako robotic technology and Da Vinci Xi robot, Fortis Bannerghatta is revolutionizing surgical outcomes and enhancing patient experiences.

First in South Asia: Fortis Memorial, Gurugram, introduces Gamma Knife Esprit for high precision brain tumour treatment

Fortis Memorial Research Institute (FMRI), Gurugram, has introduced South Asia’s first Gamma Knife Esprit radiosurgery equipment for neurosurgical treatment. The launch event and Continuing Medical Education (CME) session took place on June 15, 2024, in the presence of over 500 clinicians. The lamp lighting ceremony was graced by Dr Rana Patir, Chairman - Neurosurgery, Dr Sandeep Vaishya, Executive Director - Neuro & Spine Surgery, Mr Anil Vinayak, Group COO; Dr Bishnu Panigrahi,  Group Head – MSOG, Dr Ritu Garg, Chief Growth & Innovation Officer along with Mr Mahipal Bhanot, Senior VP & Business Head (FMRI, Shalimar Bagh, Vasant Kunj, Manesar & Defence Colony), Mr Yash Rawat, Facility Director, FMRI, Gurugram, Prof AK Banerji (Emeritus Director, AIIMS), Prof VS Mehta (Chairman Neurosurgery – Paras Health) & Dr BK Misra (Chairman Neurosurgery – PD Hinduja Hospital, Mumbai).

The ground breaking version of the Gamma Knife Esprit heralds a new era in the non-surgical high precision treatment of brain lesions. The Gamma Knife employs computer-guided precision to target brain tumours without actual cutting , making it an optimal choice for treating both malignant and benign tumours, including multiple brain metastases, meningiomas, acoustic tumours, pituitary adenomas & non-cancerous conditions like Trigeminal Neuralgia and AVMs.

Its precision is crucial for tumours in sensitive or hard-to-reach brain areas with sparing healthy brain tissues and allows patients to return to daily activities almost immediately.

On October 24, 2024, Fortis Gurugram celebrated a signi­cant milestone by completing over 100 successful Gamma Knife surgeries. The event featured a cake-cutting ceremony to honour the dedication and expertise of the Neurosurgery Department, led by Dr Rana Patir, Chairman - Neurosurgery & Gamma Knife, and Dr Sandeep Vaishya, Executive Director & HOD - Neurosurgery & Gamma Knife.

The celebration was attended by Mr Yash Rawat, Facility Director - Fortis Gurugram, along with senior clinicians and staff, who gathered to recognise the team’s commitment to excellence in neurosurgery. The occasion not only acknowledged the department’s achievements but also reinforced Fortis Gurugram's vision for clinical excellence and innovation in healthcare.

Fortis Memorial Research Institute, Gurugram, unveiled North and Central India’s ­rst MR Linac on September 5, 2024 in the presence of Mr Christian Kamill, Chargé d'Affaires a.i of the Embassy of Sweden, Dr Virender Yadav, CMO, Gurugram and Dr Ashutosh Raghuvanshi, MD & CEO, Fortis Healthcare, among others. The advanced MR Linac unit, which enables precise of targeting soft tissue cancers that are dif­cult to treat using conventional imaging and radiation techniques, is led by Dr A.K. Anand, Senior Director & Head - Radiation Oncology; Dr Swarupa Mitra, Director - Radiation Oncology; and Dr Amal Roy Chaudhoory, Director - Radiation Oncology, along with their team of radiation oncologists, physicists, and technologists.

The state-of-the-art Elekta Unity MR Linac technology integrates Magnetic Resonance Imaging (MRI) with high-energy radiation therapy, offering unparalleled precision in targeting and treating tumours. This cutting-edge innovation represents a signi­cant step forward in the ­ght against cancer, allowing real-time monitoring and treatment adjustments that minimize side effects and enhance patient outcomes.

On April 15, 2025, Fortis Gurugram launched the Fortis Institute of Genomic Medicine, a pioneering centre dedicated to harnessing the power of genomic science to transform patient care. Backed by Fortis’ advanced clinical ecosystem and Agilus Diagnostics’ extensive national footprint, the institute brings together a multi-disciplinary team of medical experts from Molecular Hematology, Oncology, Neurology, Pediatrics, Pathology and Genomic scientists along with bioinformaticians and AI (artificial intelligence) engineers.

Genomics is transforming the future of modern medicine and treatment modalities across specialties – Oncology, Cardiology, Neurology. Onco-genomics will help clinicians decode the genetic drivers of cancer, enabling targeted therapies that are more effective and less toxic than traditional one-size-fits-all treatments. Cardio-genomics will empower the early detection of inherited cardiac conditions, crucial for families with a history of sudden cardiac arrest, unexplained heart failure, or congenital heart disease. Meanwhile, Neuro-genomics will offer new hope for patients with complex neurological disorders, using gene-based insights to improve diagnosis and personalize interventions for conditions like epilepsy, Parkinson’s and rare neurodevelopmental syndromes. The power of Genomics has already delivered life-changing outcomes: a leukemia patient, initially headed for a transplant, received a new course of treatment following a precise genetic diagnosis; a woman with a silent hereditary cancer risk underwent genomic screening, leading to early detection and preventive care for three family members; and a lung cancer patient with a previously undetected MET-ST7 fusion (a genetic alteration)—identified solely through Fortis’ Next-Generation Sequencing (NGS)—is now thriving on targeted therapy.

In the near future, Fortis will also launch a Genomics-informed health registry, setting a new benchmark in precision medicine along with India’s first AI-powered genomic reporting platform designed specifically for Indian clinicians as per international recommendations by ACMG (American College of Medical Genetics and Genomics), AMP (Association for Molecular Pathology), and ASCO (American Society of Clinical Oncology), which will be  compliant, clinically relevant, and intuitively designed for seamless integration into medical practice. 

Senior clinicians and leaders present on the occasion included Dr Rahul Bhargava, Principal Director and Chief, Bone Marrow Transplant, FMRI, Gurugram; Dr Vinayak Agarwal, Senior Director & Head, Non-Invasive Cardiology, FMRI, Gurugram; Dr Praveen Gupta, Principal Director & Chief of Neurology, FMRI, Gurugram; Dr Nitesh Rohatgi, Senior Director, Medical Oncology, FMRI, Gurugram; Dr Ankur Bahl, Senior Director, Medical Oncology, FMRI, Gurugram; Dr Shrinidhi Nathany, Consultant, Molecular Haematology and Oncology, FMRI, Gurugram; Dr Ritu Garg, Chief Growth and Innovation Officer, Fortis Healthcare and Mr Yash Rawat, Facility Director, FMRI, Gurugram.